Press Releases Emyria Limited

Equities

Delayed Australian S.E. Other stock markets 22:26:58 2024-06-27 EDT			5-day change	1st Jan Change
0.042 ^AUD	+2.44%		-4.55%	-19.23%

06-20	Emyria to Facilitate PTSD Treatment Trial	MT
06-11	Emyria CFO Steps Down	MT

Emyria opens Empax Centre to target care gaps in resistant PTSD	04-10	AQ
Emyria welcomes top healthcare leader as chairman	11-22	AQ
Emyria hails strong growth in clinical billings	23-10-26	AQ
Emyria set to begin MDMA study after securing local supply	23-09-26	AQ
Emyria provides unique combination of drug development and therapy delivery	23-09-07	AQ
Emyria advances development and commercialisation of unique drug products	23-08-01	AQ
Emyria expands mental health care capabilities with Pax Centre acquisition	23-07-03	AQ
Emyria hails ethics approval for MDMA-assisted clinical trial	23-06-08	AQ
Emyria launches new high potency Ultra-Pure CBD capsule	23-04-24	AQ
Emyria agrees licensing and commercialisation deal for EMD-RX5	23-04-04	AQ
Emyria thrilled with new collaboration for MDMA-assisted PTSD therapy	23-03-08	AQ
Emyria ramps up MDMA programs following Ã¢€˜incredibleÃ¢€™ TGA decision	23-02-07	AQ
Emyria welcomes dosing of first patient in Phase 3 anxiety trial	23-01-31	AQ
Emyria delighted to be accepted into prestigious US pain initiative	22-11-29	AQ
Emyria delighted to be accepted into prestigious US pain initiative	22-11-29	EQ
Emyria : Appendix 4C - Quarterly	22-07-27	PU
Emyria : Appendix 4C - Quarterly	22-04-26	PU
Emyria : Broker Briefing Presentation	22-03-24	PU
Emyria : Addendum to Notice of Meeting and Proxy Form	22-03-18	PU
Emyria : Hidden Gems Webinar Presentation	22-03-03	PU

No results for this search